Wednesday, November 14, 2007
hypertension and vaccination
Potential Benefit of Good BP Control
Asked for comment on this work by Medscape Neurology & Neurosurgery, session moderator John M. Flack, MD, from Wayne State University, in Detroit, Michigan, said he thinks there is significant potential for this kind of approach to treating hypertension.
"There are potential safety issues — for example, in pregnant women, where angiotensin II is needed for the development of the fetus," Dr. Flack said. "On the other hand, in appropriately selected populations, this really overcomes 1 significant barrier, and that is the daily compliance required to receive the full effect of antihypertensive treatment.
"I think that once the right doses are found and the immune response and its link to blood pressure is better understood, that this is a very promising branch point in our ability to treat hypertension, a chronic condition, over the long term," he said.
The study was funded by Cytos Biotechnology AG, Schlieren, Switzerland, developer of this vaccine. Dr. Nussberger reports he received funding from Cytos for performing biochemical analyses for this study.
American Heart Association Scientific Sessions 2007: Abstract 2519. Presented November 6, 2007.
Asked for comment on this work by Medscape Neurology & Neurosurgery, session moderator John M. Flack, MD, from Wayne State University, in Detroit, Michigan, said he thinks there is significant potential for this kind of approach to treating hypertension.
"There are potential safety issues — for example, in pregnant women, where angiotensin II is needed for the development of the fetus," Dr. Flack said. "On the other hand, in appropriately selected populations, this really overcomes 1 significant barrier, and that is the daily compliance required to receive the full effect of antihypertensive treatment.
"I think that once the right doses are found and the immune response and its link to blood pressure is better understood, that this is a very promising branch point in our ability to treat hypertension, a chronic condition, over the long term," he said.
The study was funded by Cytos Biotechnology AG, Schlieren, Switzerland, developer of this vaccine. Dr. Nussberger reports he received funding from Cytos for performing biochemical analyses for this study.
American Heart Association Scientific Sessions 2007: Abstract 2519. Presented November 6, 2007.
# posted by roodbont @ 1:51 AM 
